ATE183927T1 - Arzneimittelsystem mit gelmatrix enthaltend einen immobilisierten wirkstoff - Google Patents
Arzneimittelsystem mit gelmatrix enthaltend einen immobilisierten wirkstoffInfo
- Publication number
- ATE183927T1 ATE183927T1 AT93901816T AT93901816T ATE183927T1 AT E183927 T1 ATE183927 T1 AT E183927T1 AT 93901816 T AT93901816 T AT 93901816T AT 93901816 T AT93901816 T AT 93901816T AT E183927 T1 ATE183927 T1 AT E183927T1
- Authority
- AT
- Austria
- Prior art keywords
- active ingredient
- gel matrix
- matrix containing
- polysaccharide
- immobilized active
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929200638A GB9200638D0 (en) | 1992-01-10 | 1992-01-10 | Drug system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE183927T1 true ATE183927T1 (de) | 1999-09-15 |
Family
ID=10708507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT93901816T ATE183927T1 (de) | 1992-01-10 | 1993-01-08 | Arzneimittelsystem mit gelmatrix enthaltend einen immobilisierten wirkstoff |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US5830506A (de) |
| EP (1) | EP0626862B1 (de) |
| JP (1) | JP4025363B2 (de) |
| AT (1) | ATE183927T1 (de) |
| AU (1) | AU3263093A (de) |
| DE (1) | DE69326234T2 (de) |
| DK (1) | DK0626862T3 (de) |
| ES (1) | ES2135458T3 (de) |
| GB (1) | GB9200638D0 (de) |
| GR (1) | GR3031479T3 (de) |
| WO (1) | WO1993013803A1 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9200638D0 (en) * | 1992-01-10 | 1992-03-11 | Leicester Polytechnic | Drug system |
| GB9313484D0 (en) | 1993-06-30 | 1993-08-11 | Univ Montfort | Drug system ii |
| GB9805896D0 (en) | 1998-03-20 | 1998-05-13 | Eglise David | Remote analysis system |
| EP1212601A4 (de) * | 1999-08-27 | 2006-03-29 | Biotech Inc M | Glukosebiosensor |
| JP2004507283A (ja) * | 2000-04-22 | 2004-03-11 | エム−バイオテック インコーポレイテッド | ヒドロゲルのバイオセンサとバイオセンサに基づいた健康のアラームシステム(hydrogelbiosensorandbiosensor−basedhealthalarmsystem) |
| GB0116860D0 (en) * | 2001-07-10 | 2001-09-05 | Univ Montfort | Gel compositions |
| EP1418876A4 (de) | 2001-08-17 | 2007-07-11 | Univ Pittsburgh | Verabreichung von östradiol-metaboliten zur behandlung oder prävention von adipositas, des metabolischen syndroms, von diabetes und von gefäss- und nierenerkrankungen |
| US6943267B1 (en) | 2001-08-24 | 2005-09-13 | Utah State University | Thiophosphonate inhibitors of phosphatase enzymes and metallophosphatases |
| US20080279936A1 (en) * | 2001-10-10 | 2008-11-13 | The University Of Pittsburgh | Estradiol metabolites for reduction of endothelin production |
| US20090118605A1 (en) * | 2002-08-30 | 2009-05-07 | Northwestern University | Surface-enhanced raman nanobiosensor |
| CA2509382A1 (en) | 2002-12-17 | 2004-07-08 | Todd C. Zion | Stimuli-responsive systems for controlled drug delivery |
| KR20050104383A (ko) * | 2003-02-20 | 2005-11-02 | 유니버시티 오브 피츠버그 | 폐 고혈압의 치료를 위한 에스트라디올 대사물 |
| US20060194775A1 (en) * | 2003-02-20 | 2006-08-31 | University Of Pittsburgh | Estradiol metabolites for the treatment of pulmonary hypertension |
| US7806856B2 (en) * | 2005-04-22 | 2010-10-05 | Accessclosure, Inc. | Apparatus and method for temporary hemostasis |
| US7687608B2 (en) | 2005-10-19 | 2010-03-30 | Smartcells, Inc. | Methods for reducing the mitogenicity of lectin compositions |
| BRPI1007457A2 (pt) | 2009-01-28 | 2015-08-25 | Smartcells Inc | Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba. |
| WO2010088268A1 (en) | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Exogenously triggered controlled release materials and uses thereof |
| WO2010088286A1 (en) | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Synthetic conjugates and uses thereof |
| WO2010088300A1 (en) | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Crystalline insulin-conjugates |
| US8623345B2 (en) | 2009-03-20 | 2014-01-07 | Smartcells | Terminally-functionalized conjugates and uses thereof |
| WO2010107520A1 (en) | 2009-03-20 | 2010-09-23 | Smartcells, Inc. | Soluble non-depot insulin conjugates and uses thereof |
| JP2013535467A (ja) | 2010-07-28 | 2013-09-12 | スマートセルズ・インコーポレイテツド | 組換えにより発現されたインスリンポリペプチドおよびその使用 |
| EP2598522A4 (de) | 2010-07-28 | 2014-11-12 | Smartcells Inc | Rekombinante lektine, bindungsstellenmodifizierte lektine und anwendungen davon |
| AU2011282977A1 (en) | 2010-07-28 | 2013-02-21 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
| GB201314640D0 (en) | 2013-08-15 | 2013-10-02 | Univ Montfort | Matrix gel |
| KR20160065930A (ko) | 2013-10-04 | 2016-06-09 | 머크 샤프 앤드 돔 코포레이션 | 글루코스-반응성 인슐린 접합체 |
| WO2018175272A1 (en) | 2017-03-23 | 2018-09-27 | Merck Sharp & Dohme Corp. | Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes |
| EP3727424A4 (de) | 2017-12-18 | 2021-10-27 | Merck Sharp & Dohme Corp. | Konjugatbasierte systeme für kontrollierte insulinfreisetzung |
| US11413352B2 (en) | 2017-12-18 | 2022-08-16 | Merck, Sharp & Dohme LLC | Conjugate based systems for controlled insulin delivery |
| CN114432243B (zh) * | 2022-01-20 | 2023-08-29 | 华南师范大学 | 一种响应pH和葡萄糖的纳米载体及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4348387A (en) * | 1979-07-31 | 1982-09-07 | The Rockefeller University | Method and system for the controlled release of biologically active substances to a body fluid |
| HK1002252A1 (en) * | 1991-04-02 | 1998-08-07 | Biotech Australia Pty. Limited | Oral delivery systems for microparticles |
| GB9200638D0 (en) * | 1992-01-10 | 1992-03-11 | Leicester Polytechnic | Drug system |
| GB9313484D0 (en) * | 1993-06-30 | 1993-08-11 | Univ Montfort | Drug system ii |
-
1992
- 1992-01-10 GB GB929200638A patent/GB9200638D0/en active Pending
-
1993
- 1993-01-08 EP EP93901816A patent/EP0626862B1/de not_active Expired - Lifetime
- 1993-01-08 DE DE69326234T patent/DE69326234T2/de not_active Expired - Lifetime
- 1993-01-08 AU AU32630/93A patent/AU3263093A/en not_active Abandoned
- 1993-01-08 ES ES93901816T patent/ES2135458T3/es not_active Expired - Lifetime
- 1993-01-08 AT AT93901816T patent/ATE183927T1/de not_active IP Right Cessation
- 1993-01-08 DK DK93901816T patent/DK0626862T3/da active
- 1993-01-08 US US08/256,283 patent/US5830506A/en not_active Expired - Lifetime
- 1993-01-08 JP JP51224793A patent/JP4025363B2/ja not_active Expired - Fee Related
- 1993-01-08 WO PCT/GB1993/000034 patent/WO1993013803A1/en not_active Ceased
-
1998
- 1998-07-29 US US09/124,694 patent/US7063863B2/en not_active Expired - Fee Related
-
1999
- 1999-10-08 GR GR990402571T patent/GR3031479T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GR3031479T3 (en) | 2000-01-31 |
| JP4025363B2 (ja) | 2007-12-19 |
| US20020168409A1 (en) | 2002-11-14 |
| ES2135458T3 (es) | 1999-11-01 |
| DK0626862T3 (da) | 1999-12-13 |
| EP0626862A1 (de) | 1994-12-07 |
| GB9200638D0 (en) | 1992-03-11 |
| WO1993013803A1 (en) | 1993-07-22 |
| US7063863B2 (en) | 2006-06-20 |
| AU3263093A (en) | 1993-08-03 |
| EP0626862B1 (de) | 1999-09-01 |
| DE69326234D1 (de) | 1999-10-07 |
| JPH07507268A (ja) | 1995-08-10 |
| US5830506A (en) | 1998-11-03 |
| DE69326234T2 (de) | 1999-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE183927T1 (de) | Arzneimittelsystem mit gelmatrix enthaltend einen immobilisierten wirkstoff | |
| AU628674B2 (en) | Polymer complexes of a sugar response type | |
| Sethi et al. | Study of a cross-linked hydrogel of Karaya gum and Starch as a controlled drug delivery system | |
| Singh et al. | Biomedical applications of chitin, chitosan, and their derivatives | |
| US5902607A (en) | Reversible cross-linked gel | |
| Bhardwaj et al. | Natural gums and modified natural gums as sustained-release carriers | |
| Gliko-Kabir et al. | Low swelling, crosslinked guar and its potential use as colon-specific drug carrier | |
| Kim et al. | Refined control of thermoresponsive swelling/deswelling and drug release properties of poly (N-isopropylacrylamide) hydrogels using hydrophilic polymer crosslinkers | |
| KR880010769A (ko) | 안정한 안과용 수성 조성물 및 그 제조방법 | |
| ES2093625T3 (es) | Administracion extendida de farmaco de moleculas pequeñas solubles en agua. | |
| Liao et al. | Temperature/pH dual sensitive Hericium erinaceus residue carboxymethyl chitin/poly (N-isopropyl acrylamide) sequential IPN hydrogels | |
| GB1283857A (en) | Size for glass fibres | |
| CA2067228A1 (en) | Drug delivery system, method for preparing the same and use thereof | |
| Verestiuc et al. | Functionalized chitosan/NIPAM (HEMA) hybrid polymer networks as inserts for ocular drug delivery: Synthesis, in vitro assessment, and in vivo evaluation | |
| KR920002155A (ko) | 슈크랄페이트(Sucralfate) 저작성 타블렛 | |
| JP3647859B2 (ja) | 酵素的に制御された薬剤放出のための架橋されたポリヒドロキシ材料 | |
| KR950031053A (ko) | 이온성 고분자 네트웍을 갖는 피부약물전달체계 | |
| Landale et al. | Characterization by affinity electrophoresis of an alpha-1, 6-glucan-binding protein from Streptococcus sobrinus | |
| US4379038A (en) | Process for preparing a physiologically active substance controlled release composite composition | |
| JPH06100468A (ja) | 徐放性組成物 | |
| Viyoch et al. | Development of hydrogel patch for controlled release of alpha‐hydroxy acid contained in tamarind fruit pulp extract | |
| US5215752A (en) | Pharmaceutical tablets and capsule granulates of scleroglucan and active substance | |
| EP0333105B1 (de) | Scleroglucan und Wirkstoff enthaltende pharmazeutische Tabletten und Kapselgranulate | |
| Jawad | A Review On Novel Approach Of Drug Delivery–Hydrogels | |
| Kaczmarek-Szczepańska | Dual-cross-linked nanocomposite hydrogels for potential antibacterial applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |